AusDiagnostics has included its dual target SARS-CoV-2, Influenza and RSV panel in the Australian Register of Therapeutic Goods.
- The panel achieved 100 per cent sensitivity and 100 per cent specificity in a study of 210 samples including 44 from COVID-19 patients. The work was carried out by scientists at Sydney’s Westmead Hospital and presented to the Therapeutic Goods Administration last week.
- The panel has two targets for SARS-CoV-2, one in ORF 1a and one in ORF 8. Using two targets makes the test more robust if mutations in the virus occur. The other targets in the panel detect respiratory illnesses with similar symptoms.
- The multiplexed tandem PCR technology used by AusDiagnostics allows a low limit of detection to be achieved with clinical samples. Some samples could be diluted 1,000,000 fold and still were successfully detected.
The AusDiagnostics respiratory virus panel is manufactured and approved for use by the Therapeutic Goods Administration (TGA) .
Buy the AusDiagnostics respiratory virus panel for Your WorkPlace
If your company or organisation is interested in rapid testing solutions, contact us today for help procuring the AusDiagnostics respiratory virus panel for detecting SARS-CoV-2 or other rapid tests authorised by the Therapeutic Goods Administration (TGA) .
If you’re interested in rapid testing solutions, contact us today for a quote. You can also place an order for the AusDiagnostics respiratory virus panel or other rapid tests approved by the TGA.
Our team at Rapid Tests Australia can also assist with implementing a rapid testing program to protect your workplace from the risks of COVID-19.